278 related articles for article (PubMed ID: 31243347)
21. Over-Expression of TBL1XR1 Indicates Poor Prognosis of Serous Epithelial Ovarian Cancer.
Ma M; Yu N
Tohoku J Exp Med; 2017 Mar; 241(3):239-247. PubMed ID: 28344213
[TBL] [Abstract][Full Text] [Related]
22. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
[TBL] [Abstract][Full Text] [Related]
23. MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin.
Zhao H; Xie YZ; Xing R; Sun M; Chi F; Zeng YC
Cell Oncol (Dordr); 2017 Aug; 40(4):357-365. PubMed ID: 28567715
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA‑29a enhances cisplatin sensitivity in non‑small cell lung cancer through the regulation of REV3L.
Chen X; Zhu H; Ye W; Cui Y; Chen M
Mol Med Rep; 2019 Feb; 19(2):831-840. PubMed ID: 30535450
[TBL] [Abstract][Full Text] [Related]
25. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
26. Identification of a potential tumor suppressor gene,
Zhao X; Yongchun Z; Qian H; Sanhui G; Jie L; Hong Y; Yanfei Z; Guizhen W; Yunchao H; Guangbiao Z
Cancer Biol Med; 2020 Feb; 17(1):76-87. PubMed ID: 32296577
[No Abstract] [Full Text] [Related]
27. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
[TBL] [Abstract][Full Text] [Related]
28. TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway.
Xing Y; Liu Y; Liu T; Meng Q; Lu H; Liu W; Hu J; Li C; Cao M; Yan S; Huang J; Wang T; Cai L
Cell Commun Signal; 2018 Jul; 16(1):43. PubMed ID: 30064446
[TBL] [Abstract][Full Text] [Related]
29. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW
Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
[TBL] [Abstract][Full Text] [Related]
30. LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway.
Liu L; Zhou XY; Zhang JQ; Wang GG; He J; Chen YY; Huang C; Li L; Li SQ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8722-8730. PubMed ID: 30575912
[TBL] [Abstract][Full Text] [Related]
31. TAB3 overexpression promotes cell proliferation in non-small cell lung cancer and mediates chemoresistance to CDDP in A549 cells via the NF-κB pathway.
Chen J; Gu J; Feng J; Liu Y; Xue Q; Ni T; Wang Z; Jia L; Mao G; Ji L
Tumour Biol; 2016 Mar; 37(3):3851-61. PubMed ID: 26476534
[TBL] [Abstract][Full Text] [Related]
32. Krüppel-like factor 4 promotes c-Met amplification-mediated gefitinib resistance in non-small-cell lung cancer.
Feng W; Xie Q; Liu S; Ji Y; Li C; Wang C; Jin L
Cancer Sci; 2018 Jun; 109(6):1775-1786. PubMed ID: 29624806
[TBL] [Abstract][Full Text] [Related]
33. Long noncoding RNA SNHG7 contributes to cell proliferation, migration, invasion and epithelial to mesenchymal transition in non-small cell lung cancer by regulating miR-449a/TGIF2 axis.
Pang L; Cheng Y; Zou S; Song J
Thorac Cancer; 2020 Feb; 11(2):264-276. PubMed ID: 31793741
[TBL] [Abstract][Full Text] [Related]
34. MiR-129-5p inhibits non-small cell lung cancer cell stemness and chemoresistance through targeting DLK1.
Ma Z; Cai H; Zhang Y; Chang L; Cui Y
Biochem Biophys Res Commun; 2017 Aug; 490(2):309-316. PubMed ID: 28619508
[TBL] [Abstract][Full Text] [Related]
35. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells.
Jiang P; Wu X; Wang X; Huang W; Feng Q
Oncotarget; 2016 Jul; 7(28):43337-43351. PubMed ID: 27270317
[TBL] [Abstract][Full Text] [Related]
36. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
37. Knockdown of LncRNA PVT1 inhibits tumorigenesis in non-small-cell lung cancer by regulating miR-497 expression.
Guo D; Wang Y; Ren K; Han X
Exp Cell Res; 2018 Jan; 362(1):172-179. PubMed ID: 29133127
[TBL] [Abstract][Full Text] [Related]
38. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
[TBL] [Abstract][Full Text] [Related]
39. miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met.
Cao X; Lai S; Hu F; Li G; Wang G; Luo X; Fu X; Hu J
Sci Rep; 2017 Jun; 7(1):2939. PubMed ID: 28592790
[TBL] [Abstract][Full Text] [Related]
40. Interferon regulatory factor 4 (IRF4) is overexpressed in human non‑small cell lung cancer (NSCLC) and activates the Notch signaling pathway.
Qian Y; Du Z; Xing Y; Zhou T; Chen T; Shi M
Mol Med Rep; 2017 Nov; 16(5):6034-6040. PubMed ID: 28849037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]